Analysis of prognostic factors and treatment of anaplastic meningioma in China.
Meningioma is the most frequently reported primary brain and central nervous system tumor. However, malignant meningioma is rare with the anaplastic subtype the most common. This subtype of meningioma is fatal with a high recurrence rate and poor survival. A retrospective review of anaplastic meningioma patients treated in one of the largest neurosurgical centers in China between 2003 and 2008 was conducted. From 70 identified patients, seven were lost to follow-up, but the remaining 63 patients were studied for prognostic factors. The mean follow-up time was 84.9±standard deviation (SD) of 19.7months. Tumor recurred in 35 out of 63 (55.6%) patients. Thirty-three (52.4%) patients had died by the most recent follow-up, and the median overall survival (OS) was 70.0±9.7months. The 3year and 5year survival rates were 68.3% and 54.7%, respectively. The median progression-free survival (PFS) was 52.0±9.9months, whereas the 3year and 5year PFS rates were 60.2% and 43.9%, respectively. We found that preoperative KPS, extent of tumor resection, radiotherapy, tumor location and previous history of meningioma were factors related to PFS. In the non-recurrent group, the preoperative Karnofsky Performance Scale (KPS), extent of tumor resection and radiotherapy correlated with PFS. However, multivariate analysis identified radiotherapy as the only independent factor affecting PFS (p=0.007). Additionally, MIB-1 proliferation index failed to identify a cut-off point to predict the prognosis for anaplastic meningioma. This study provides an overview of the epidemiology and treatment of anaplastic meningioma in China using a large population.
Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12# Wu Lu Mu Qi Road, Shanghai 200040, China.
Hongda
H
Zhu
Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12# Wu Lu Mu Qi Road, Shanghai 200040, China.
Qing
Q
Xie
Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12# Wu Lu Mu Qi Road, Shanghai 200040, China.
Yu
Y
Zhou
Department of Neuropathology, Huashan Hospital, Fudan University, Shanghai, China.
Hong
H
Chen
Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12# Wu Lu Mu Qi Road, Shanghai 200040, China.
Ying
Y
Mao
Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12# Wu Lu Mu Qi Road, Shanghai 200040, China.
Ping
P
Zhong
Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12# Wu Lu Mu Qi Road, Shanghai 200040, China.
Kang
K
Zheng
Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12# Wu Lu Mu Qi Road, Shanghai 200040, China.
Yongfei
Y
Wang
Department of Neuropathology, Huashan Hospital, Fudan University, Shanghai, China.
Yin
Y
Wang
Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12# Wu Lu Mu Qi Road, Shanghai 200040, China.
Liqian
L
Xie
Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12# Wu Lu Mu Qi Road, Shanghai 200040, China.
Mingzhe
M
Zheng
Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12# Wu Lu Mu Qi Road, Shanghai 200040, China.
Hailiang
H
Tang
Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12# Wu Lu Mu Qi Road, Shanghai 200040, China.
Daijun
D
Wang
Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12# Wu Lu Mu Qi Road, Shanghai 200040, China.
Xiancheng
X
Chen
Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12# Wu Lu Mu Qi Road, Shanghai 200040, China.
Liangfu
L
Zhou
Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12# Wu Lu Mu Qi Road, Shanghai 200040, China. Electronic address: drgongye@163.com.
Ye
Y
Gong
D000328:Adult; D000368:Aged; D002277:Carcinoma / Q000453:epidemiology* / Q000473:pathology / Q000601:surgery; D016543:Central Nervous System Neoplasms / Q000453:epidemiology* / Q000473:pathology / Q000601:surgery; D059186:Chemoradiotherapy, Adjuvant; D002681:China / Q000453:epidemiology; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D019098:Telomerase / Q000032:analysis / Q000378:metabolism; D055815:Young Adult
D019098:Telomerase
Anaplastic meningioma; Overall survival; Progression free survival; Radiotherapy; Recurrence